---
title: "300573.SZ (300573.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300573.SZ/news.md"
symbol: "300573.SZ"
name: "300573.SZ"
parent: "https://longbridge.com/en/quote/300573.SZ.md"
datetime: "2026-05-21T03:51:10.514Z"
locales:
  - [en](https://longbridge.com/en/quote/300573.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300573.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300573.SZ/news.md)
---

# 300573.SZ (300573.SZ) — Related News

### [Xingqi Pharmaceutical: The effect of lidocaine hydrochloride eye gel for ocular surface anesthesia is comparable to that of the original research product](https://longbridge.com/en/news/285912348.md)
*2026-05-11T09:04:09.000Z*
> Xingqi Pharmaceutical (300573) released a summary report of the Phase III clinical trial for lidocaine hydrochloride eye

### [The OK Mirror policy seal has finally been lifted, but the good days for OK Mirror have also come to an end](https://longbridge.com/en/news/284592054.md)
*2026-04-29T13:55:21.000Z*
> The National Health Commission released the "Clinical Application Management Specifications for Orthokeratology Lens Fit

### [Xingqi Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 206 million yuan, an increase of 41.48%](https://longbridge.com/en/news/284179531.md)
*2026-04-27T08:48:06.000Z*
> Xingqi Pharmaceutical released its Q1 2026 performance, with operating revenue of 683 million yuan, a year-on-year incre

### [Ophthalmology medical concept remains active against the trend, Bright Eye Hospital Group rises over 10%](https://longbridge.com/en/news/283921946.md)
*2026-04-24T02:16:42.000Z*
> The ophthalmology medical concept is active against the trend, with Bright Eye Hospital Group rising over 10%. Aier, Xin

### [Xingqi Pharmaceutical's net profit will double by 2025, and competitors for atropine will arrive](https://longbridge.com/en/news/283703910.md)
*2026-04-22T17:03:35.000Z*
> Xingqi Pharmaceutical released its 2025 annual report, with total operating revenue of 2.473 billion yuan, a year-on-yea

### [Xingqi Pharmaceutical released its 2025 annual performance, with a net profit attributable to the parent company of 696 million yuan, an increase of 105.84%](https://longbridge.com/en/news/283481969.md)
*2026-04-21T10:39:18.000Z*
> Xingqi Pharmaceutical released its annual report for 2025, with operating revenue of 2.473 billion yuan, a year-on-year 

### [Xingqi Pharmaceutical has obtained a drug registration certificate](https://longbridge.com/en/news/281615864.md)
*2026-04-03T07:48:04.000Z*
> Xingqi Pharmaceutical announced that the company has obtained the "Drug Registration Certificate" for Brimonidine Tartra

### [Xingqi Pharmaceutical SQ-24071 starts clinical trials: lengthy development, intensified competition, new pipeline difficult to save short-term performance](https://longbridge.com/en/news/278837296.md)
*2026-03-12T07:19:11.000Z*
> Xingqi Pharmaceutical announced that its self-developed SQ-24071 eye drops have completed the enrollment of the first su

### [Xingqi Pharmaceutical: The first subject enrolled in the Phase I clinical trial of SQ-24071 eye drops](https://longbridge.com/en/news/278702988.md)
*2026-03-11T10:33:05.000Z*
> Xingqi Pharmaceutical announced that the first subject has been enrolled in the Phase I clinical trial of its developed